NextDocs Corporation Expands Its Operations to Europe
Provides Microsoft Office SharePoint Server-Based Document and Quality Management Solutions for Life Sciences Industry
Munich, Germany -- NextDocs Corporation <http://www.nextdocs.com/> , a leading provider of Microsoft Office SharePoint Server-based regulatory document and quality management software, announced today that is has opened a branch office in Germany. NextDocs' line of fully FDA 21 CFR Part 11 compliant SharePoint Server-based document and quality management solutions has been developed specifically for life sciences companies to enhance productivity and reduce risk.
The new office, located in Munich, will provide local sales and technical support for the European customer base. The European subsidiary will play a vital role in the global expansion of NextDocs and enable rapid growth in the European market.
"Because our main customers are based in Central Europe, the establishment of a NextDocs presence in Munich will allow us to continue our phenomenal momentum. It is a tremendous growth opportunity for our company, and it is only the first step of our fast-growing expansion in Europe. Our intention is to provide our European customer and partners with the best available local support," said NextDocs Chief Executive Officer Zikria Syed.
Rainer Schwarz has been named NextDoc's General Manager and Sales Director for the European operation.
"I am very glad to be part of NextDocs," Mr. Schwarz said. "As NextDocs moves to the next level of corporate development, the opening of this first office in Europe is an important step for our company. The demand in the life sciences market for SharePoint Server-based content management solutions continues to be enormous. Thanks to our enhanced presence on the continent, we can focus our activities in the European time zone, provide first class support and work more closely with our customers."
The European office is located in Elisabethstrasse 91, 80797 Munich, Germany.
Tel: +49 (0) 89 5908-1210 and Fax: +49 (0) 89 5908-1200
"NextDocs Document and Quality Management suite provides a comprehensive solution based on Microsoft Office SharePoint Server that allows our life sciences customers to take full advantage of their existing Microsoft technology investments, while solving key business problems," said Ruediger Dorn, Managing Director, Worldwide Pharmaceutical Industry, Microsoft Corporation. "We are happy to partner with NextDocs to roll these solutions to the European pharmaceutical community."
About NextDocs
NextDocs is a leading provider of fully FDA 21 CFR Part 11 compliant Microsoft Office SharePoint Server-based document and quality management solutions for the life sciences companies. Our mission is to deliver cost-effective, easy-to-use document management software that provides immediate productivity increases for companies operating in regulatory environments. NextDocs customers include pharmaceutical companies, bio-techs, medical device companies and CROs. For more information please visit www.nextdocs.com <http://www.nextdocs.com/> or email information@nextdocs.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.